HemoSonics is a medical device technology company that provides solutions for point-of-care viscoelastic hemostasis testing through its Quantra® System.

The company is a category award winner for Business Expansion and Product Launches in the 2023 Medical Device Network Excellence Awards, as it hit further milestones in the development of its testing solutions, specifically obtaining FDA clearance and commercializing the Quantra System with the QStat® Cartridge and securing an innovative technology contract award from Vizient.

Hemosonics Quantra Hemostasis Analyzer

The Quantra System provides comprehensive whole blood coagulation analysis at the point-of-care (POC), laboratory, and other hospital settings in less than 15 minutes, and consists of a hemostasis analyzer with QPlus® and QStat Cartridges. The Quantra System is the only viscoelastic testing solution that utilizes a proprietary ultrasound-based technology (SEER Sonorheometry) to deliver highly accurate and precise measurements when seconds matter.

Hemosonics QDRV Viewing Screens QPlus

During the award evaluation period, the company achieved significant milestones when it secured US Food and Drug Administration (FDA) 510(k) clearance for the QStat Cartridge and successfully commercialized the use of this cartridge with the Quantra System in trauma and liver transplant surgery procedures.

In addition, the company received an innovative technology contract from Vizient, one of the largest member-driven healthcare performance improvement companies in the United States. Vizient members account for more than half of the country’s acute care hospitals and 97% of academic medical centers. Vizient Innovative Technology contracts are awarded to highlight products with clear benefits for healthcare organizations. It opens the door for the Quantra System to be adopted by hospitals and academic medical centers across the United States.

Company Profile

HemoSonics, LLC is a medical device technology company focused on acute bleeding management, resulting in better patient care and lower overall medical costs.

The Quantra Hemostasis Analyzer, HemoSonics’ flagship product, is designed to improve patient outcomes and reduce healthcare costs by providing optimized information.

The Quantra System’s easy and fast interpretation enables simple, more efficient, point-of-care bleeding management.

Based in Durham, NC, HemoSonics is part of the Stago Group, a leading in vitro diagnostics company dedicated to exploring thrombosis and hemostasis.

Contact details

Mindy Hull – hemosonics@wearemgp.com

4020 Stirrup Creek Dr, Suite 105

Durham, NC 27703-8970

United States